2-[(2-氨基-2-氧乙基)硫代]苯甲酸 | 197236-53-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-[(2-氨基-2-氧乙基)硫代]苯甲酸
• 英文名称: 2-carbamoylmethylsulfanyl-benzoic acid
• 英文别名: 2-Carbamoylmethylmercapto-benzoesaeure；2-[(2-Amino-2-oxoethyl)thio]benzoic acid；2-(2-amino-2-oxoethyl)sulfanylbenzoic acid
• CAS: 197236-53-6
• 化学式: C₉H₉NO₃S
• mdl: MFCD00031447
• 分子量: 211.241
• InChiKey: CTLJJQVIQIPRFS-UHFFFAOYSA-N

物化性质

• 沸点：
  446.9±30.0 °C(Predicted)
• 密度：
  1.42±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.111
• 拓扑面积：
  106
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-[(2-氨基-2-氧乙基)硫代]苯甲酸 在 丙酸酐 作用下， 生成 1-(3-hydroxybenzo[b]thiophen-2-yl)propan-1-one
  参考文献：
  名称：

  McClelland et al., Journal of the Chemical Society, 1948, p. 81,84

  摘要：

  DOI：
• 作为产物：
  描述：

  硫代水杨酸 、 氯乙酰胺 在 sodium hydroxide 作用下， 生成 2-[(2-氨基-2-氧乙基)硫代]苯甲酸
  参考文献：
  名称：

  McClelland; Reissert; Bartlett, Journal of the Chemical Society, 1940, p. 325

  摘要：

  DOI：

文献信息

• ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS
  申请人：Yamagishi Tatsuya

  公开号：US20120232052A1

  公开（公告）日：2012-09-13

  The present invention relates to aryl carboxamide derivatives of formula (I), wherein Ar 1 is phenyl; Ar 2 is aryl; n is 1-4; X is —O—, —S—, —SO— or —SO 2 —, a prodrug thereof or a pharmaceutically acceptable salt thereof, which have blocking activities of voltage gated sodium channels as the TTX-S channels, and which are useful in the treatment or prevention of such disorders and diseases as pain in which voltage gated sodium channels are involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases as pain in which voltage gated sodium channels are involved.

  本发明涉及公式（I）的芳基羧酰胺衍生物，其中Ar1是苯基；Ar2是芳基；n为1-4；X为—O—、—S—、—SO—或—SO2—，其前体药物或其药学上可接受的盐，具有阻断电压门控钠通道如TTX-S通道的活性，并在治疗或预防涉及电压门控钠通道的疾病和疾病，如疼痛方面中有用。本发明还涉及包含这些化合物的制药组合物以及这些化合物和组合物在预防或治疗涉及电压门控钠通道的疾病和疾病，如疼痛方面的使用。
• Recurrent focal segmental glomerulosclerosis in grafts treated with plasma exchange and increased immunosuppression
  作者：M. A. Saleem、A. V. Ramanan、L. Rees

  DOI：10.1007/s004670050774

  日期：2000.4

  We report on three children with severe, recurrent focal segmental glomeruloscerosis (FSGS) in their first allografts, treated with methylprednisolone, plasma exchange and cyclophosphamide. This protocol is based on a previous publication showing its successful use in three children. Our patients were 2 girls and 1 boy, aged 14.5, 14.6 and 13.2 years, respectively, at transplant. Concomitant immunosuppression included cyclosporin A and prednisolone. Recurrence occurred in all three patients within 24 h, and specific treatment was commenced within 48 h. All patients developed anuria and were dialysed. The boy stopped dialysis after 4 weeks, and has stable chronic renal failure (CRF) and no proteinuria 3 years later. One girl required dialysis for 4 months, and 3 years later has CRF with non-nephrotic range proteinuria. The other girl remained dialysis-dependent and died from septic complications. We conclude that even anuric patients treated with this protocol may have an improvement in renal function and reduction of proteinuria, which can last for over 3 years. However, treatment may need to be prolonged and carries the substantial risks of heavy immunosuppression.
• SALTS OF PAROXETINE
  申请人：SMITHKLINE BEECHAM PLC

  公开号：EP1091958A1

  公开（公告）日：2001-04-18
• US9051296B2
  申请人：——

  公开号：US9051296B2

  公开（公告）日：2015-06-09
• [EN] SALTS OF PAROXETINE<br/>[FR] SELS DE PAROXETINE
  申请人：SMITHKLINE BEECHAM PLC

  公开号：WO2000001692A1

  公开（公告）日：2000-01-13

  Piperidine compounds, processes for preparing them, pharmaceutical compositions comprising them and their use in therapy are disclosed.